

Application No. 10/765,678  
SD-7463

## REMARKS

### Claim Status:

- Claims 1-29 are pending.
- Claims 8-28 are cancelled.
- Claims 1-7 and 29 are rejected.

RECEIVED  
CENTRAL FAX CENTER  
OCT 10 2006

### Claim Amendments

- Claims 1-3 and 6-7 are currently amended in this paper.

### Claim Rejections

#### Claims 1-7 and 29

The Office rejected claims 1-7 and 29 under 35 USC §112, first paragraph, as adding new matter

In response, applicants have amended claims 1-7 and 29 to replace "**comprising**" with "**consisting essentially of**". The specification and claims as filed fully support this change, and no new matter has been added.

#### Claims 1-4, 6-7 and 29

The Office rejected claims 1-4, 6-7 and 29 under 35 USC §102(b) as being anticipated by, or in the alternative, under 35 USC 103(a) as obvious over *Nakagawa et al.* (3,901,819).

In response, applicants amended claims 1-7 and 29 to replace "**comprising**" with "**consisting essentially of**".

The term "**short-chained organic compounds that contain an ester bond**" was deleted from the claims.

Also, the phrase "*wherein said formulation does not comprise a solubilizing compound selected from the group consisting of a cationic surfactant, a cationic*

Application No. 10/765,678  
SD-7463

*hydrotrope, and a fatty alcohol comprising 8-20 carbon atoms*" was deleted from claims 1 and 6.

In claim 2, "ethanol" and "freeze-point depressant" was deleted.

In claim 3, "said freeze-point depressant comprises propylene glycol" was deleted.

Claim 4 was rewritten in independent form, including the limitations of base claim 1 (as currently amended).

In claim 7, benzalkonium chloride and propylene glycol were eliminated.

Claims 1-7 and 29, as currently amended, are now in condition for allowance.

Best Available Copy

Application No. 10/765,678  
SD-7463


RECEIVED  
CENTRAL FAX CENTER  
OCT 10 2006

CONCLUSION

Applicants have responded to the Advisory office action with a RCE. Applicants submit that Claims 1-7 and 29, as currently amended, are now in condition for allowance.

The Office is authorized to charge Deposit Account # 19-0131 for any necessary fees regarding this response, including extensions of time.

Respectfully submitted,



Robert D. Watson  
Reg. No. 45,604


Ph: (505) 845-3139  
Fax: (505) 844-2829  
e-mail: rdwatso@sandia.gov

Sandia National Laboratories  
P.O. Box 5800 MS-0161  
Albuquerque, NM 87185-0161

Customer No. 20567

Certificate of Transmission under 37 CFR 1.10

I hereby certify that this correspondence was transmitted via facsimile to the U.S. Patent and Trademark Office at phone number 571-273-8300 on Oct. 10, 2006.



Robert D. Watson